Notwithstanding encouraging clinical results, copyright's Vyndamax, a medication for hereditary transthyretin-mediated amyloidosis (hATTR), is experiencing significant difficulty from pharmacy benefit managers. These organizations are frequently erecting limitations to coverage, like significant price criteria and approval processes that limit p… Read More